3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Breast Neoplasms
53
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Neoplasms
3
Inflammatory Breast Neoplasms
3
HER2-positive Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Endocrine Neoplasia
1
Malignant Solid Neoplasm
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
Her2-Positive Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
Oxaliplatin
53
Cisplatin
52
Fluorouracil
50
Capecitabine
48
pembrolizumab
39
Leucovorin
31
Docetaxel
26
Trastuzumab
23
Paclitaxel
20
Irinotecan
20
Ramucirumab
13
Bevacizumab
12
Cetuximab
9
Radiotherapy
8
Surgical Procedures, Operative
7
S 1 (combination)
7
Nivolumab
7
Epirubicin
7
Carboplatin
6
olaparib
5
Platinum
5
Everolimus
5
Sunitinib
4
Mitomycin
4
trastuzumab deruxtecan
3
lenvatinib
3
epacadostat
3
bemarituzumab
3
apatinib
3
Saline Solution
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Stomach Neoplasms
×
pertuzumab
×
Clear all
NCT01774786
2020-12-30
JACOB
Hoffmann-La Roche
Phase 3
Completed
780 enrolled
24 charts
NCT01461057
2018-08-09
JOSHUA
Hoffmann-La Roche
Phase 2
Completed
30 enrolled
9 charts